SCHEDULE 13G: Adage Capital Management Discloses 5.22% Stake in Centessa Pharmaceuticals plc
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 5.22% beneficial ownership stake in Centessa Pharmaceuticals plc, totaling 6,954,000 ordinary shares.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership in Centessa Pharmaceuticals plc.
- The Reporting Persons collectively beneficially own 6,954,000 ordinary shares of Centessa Pharmaceuticals plc.
- This ownership represents 5.22% of the total outstanding ordinary shares of the company.
- The calculation of the percentage is based on 133,184,349 ordinary shares outstanding as of March 10, 2025, as reported in Centessa's Annual Report on Form 10-K filed on March 24, 2025.
- Adage Capital Management, L.P. is a Delaware limited partnership, while Robert Atchinson and Phillip Gross are citizens of the United States.
- The Reporting Persons hold shared voting and shared dispositive power over all 6,954,000 shares.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm like Adage Capital Management can be interpreted as a mildly positive signal of confidence in the issuer, Centessa Pharmaceuticals plc, by a major institutional player.
Positives
- A significant institutional investor, Adage Capital Management, L.P., has taken a substantial 5.22% stake in Centessa Pharmaceuticals plc, which may signal confidence in the company's future prospects and strategic direction.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in the biotechnology/pharmaceutical sector, a common activity for large investment funds seeking exposure to specific companies or therapeutic areas. The disclosure of a new substantial shareholder can be a point of interest for market participants tracking investment trends within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional shareholder may increase investor confidence and potentially influence trading activity and market perception of Centessa Pharmaceuticals plc.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date as of which 133,184,349 Ordinary Shares were outstanding, used for percentage calculation. |
| 03/24/2025 | Date Centessa Pharmaceuticals plc filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/12/2025 | Date the Schedule 13G statement was signed and filed by the Reporting Persons. |
Keywords
Centessa Pharmaceuticals, Adage Capital Management, beneficial ownership, Schedule 13G, institutional investment, ordinary shares, ADSs, CNTA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.